Browsing Tag
OLUMIANT
4 posts
Chemomab Therapeutics (CMMB) and Scipher Medicine to merge in $150m reverse deal
Scipher Medicine and Chemomab are merging in all-stock deal, taking Scipher public via reverse merger. $30M PIPE led by Northpond. Q4 2026 close, H1 2028 Phase 2 data.
Lilly’s Olumiant moves closer to European approval for teen alopecia patients as CHMP issues positive opinion
Eli Lilly's Olumiant wins CHMP backing for adolescent alopecia areata with 42% response rates — EU approval imminent, U.S. decision due late 2026. Read the full analysis.
Could Eli Lilly and Incyte’s Olumiant redefine how adolescent alopecia areata is treated in 2025?
Find out how Eli Lilly and Incyte's Olumiant helped teens regrow hair in a new trial—could this redefine alopecia areata treatment for adolescents?
Lilly Covid drug trial : US pharma giant launches phase 3 trial of baricitinib
Lilly Covid drug trial : Eli Lilly and Company has enrolled the first patient in a phase 3…